Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
1 file | 622.09 KB
Add to list
  1. Search results
  2. Flow cytometric minimal residual dise...

Flow cytometric minimal residual disease assessment in B‐cell precursor acute lymphoblastic leukaemia patients treated with CD19‐targeted therapies : a EuroFlow study

Martijn W. C. Verbeek, Chiara Buracchi, Anna Laqua, Stefan Nierkens, Lukasz Sedek, Juan Flores‐Montero, Mattias Hofmans (UGent) , Elaine Sobral de Costa, Michaela Nováková, Ester Mejstrikova, et al.
(2022) BRITISH JOURNAL OF HAEMATOLOGY. 197(1). p.76-81
Author
Organization
Abstract
The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.
Keywords
Hematology, acute leukaemia, diagnostic haematology, minimal residual disease, flow cytometry

Downloads

  • Download
    published.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 622.09 KB

Citation

Please use this url to cite or link to this publication:

MLA
Verbeek, Martijn W. C., et al. “Flow Cytometric Minimal Residual Disease Assessment in B‐cell Precursor Acute Lymphoblastic Leukaemia Patients Treated with CD19‐targeted Therapies : A EuroFlow Study.” BRITISH JOURNAL OF HAEMATOLOGY, vol. 197, no. 1, 2022, pp. 76–81, doi:10.1111/bjh.17992.
APA
Verbeek, M. W. C., Buracchi, C., Laqua, A., Nierkens, S., Sedek, L., Flores‐Montero, J., … Velden, V. H. J. (2022). Flow cytometric minimal residual disease assessment in B‐cell precursor acute lymphoblastic leukaemia patients treated with CD19‐targeted therapies : a EuroFlow study. BRITISH JOURNAL OF HAEMATOLOGY, 197(1), 76–81. https://doi.org/10.1111/bjh.17992
Chicago author-date
Verbeek, Martijn W. C., Chiara Buracchi, Anna Laqua, Stefan Nierkens, Lukasz Sedek, Juan Flores‐Montero, Mattias Hofmans, et al. 2022. “Flow Cytometric Minimal Residual Disease Assessment in B‐cell Precursor Acute Lymphoblastic Leukaemia Patients Treated with CD19‐targeted Therapies : A EuroFlow Study.” BRITISH JOURNAL OF HAEMATOLOGY 197 (1): 76–81. https://doi.org/10.1111/bjh.17992.
Chicago author-date (all authors)
Verbeek, Martijn W. C., Chiara Buracchi, Anna Laqua, Stefan Nierkens, Lukasz Sedek, Juan Flores‐Montero, Mattias Hofmans, Elaine Sobral de Costa, Michaela Nováková, Ester Mejstrikova, Susana Barrena, Saskia Kohlscheen, Monika Szczepanowski, Jan Kulis, Elen Oliveira, Romana Jugooa, Anja X. Jong, Tomasz Szczepanski, Jan Philippé, Jacques J. M. Dongen, Alberto Orfao, Monika Brüggemann, Giuseppe Gaipa, and Vincent H. J. Velden. 2022. “Flow Cytometric Minimal Residual Disease Assessment in B‐cell Precursor Acute Lymphoblastic Leukaemia Patients Treated with CD19‐targeted Therapies : A EuroFlow Study.” BRITISH JOURNAL OF HAEMATOLOGY 197 (1): 76–81. doi:10.1111/bjh.17992.
Vancouver
1.
Verbeek MWC, Buracchi C, Laqua A, Nierkens S, Sedek L, Flores‐Montero J, et al. Flow cytometric minimal residual disease assessment in B‐cell precursor acute lymphoblastic leukaemia patients treated with CD19‐targeted therapies : a EuroFlow study. BRITISH JOURNAL OF HAEMATOLOGY. 2022;197(1):76–81.
IEEE
[1]
M. W. C. Verbeek et al., “Flow cytometric minimal residual disease assessment in B‐cell precursor acute lymphoblastic leukaemia patients treated with CD19‐targeted therapies : a EuroFlow study,” BRITISH JOURNAL OF HAEMATOLOGY, vol. 197, no. 1, pp. 76–81, 2022.
@article{8732009,
  abstract     = {{The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.}},
  author       = {{Verbeek, Martijn W. C. and Buracchi, Chiara and Laqua, Anna and Nierkens, Stefan and Sedek, Lukasz and Flores‐Montero, Juan and Hofmans, Mattias and Sobral de Costa, Elaine and Nováková, Michaela and Mejstrikova, Ester and Barrena, Susana and Kohlscheen, Saskia and Szczepanowski, Monika and Kulis, Jan and Oliveira, Elen and Jugooa, Romana and Jong, Anja X. and Szczepanski, Tomasz and Philippé, Jan and Dongen, Jacques J. M. and Orfao, Alberto and Brüggemann, Monika and Gaipa, Giuseppe and Velden, Vincent H. J.}},
  issn         = {{0007-1048}},
  journal      = {{BRITISH JOURNAL OF HAEMATOLOGY}},
  keywords     = {{Hematology,acute leukaemia,diagnostic haematology,minimal residual disease,flow cytometry}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{76--81}},
  title        = {{Flow cytometric minimal residual disease assessment in B‐cell precursor acute lymphoblastic leukaemia patients treated with CD19‐targeted therapies : a EuroFlow study}},
  url          = {{http://doi.org/10.1111/bjh.17992}},
  volume       = {{197}},
  year         = {{2022}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: